Evidence map›Paper›PMID 31138299›Full record

ArticleJournal for immunotherapy of cancer2019

Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.

Pooja Ghatalia, Jennifer Gordetsky, Fengshen Kuo, Essel Dulaimi, Kathy Q Cai, Karthik Devarajan, Sejong Bae, Gurudatta Naik, Timothy A Chan, Robert Uzzo and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 107 papers.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 175 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Exploring the role of CD8FEBS open bio · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Pooja GhataliaFox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA. Pooja.ghatalia@tuhs.temple.edu.
Jennifer GordetskyUniversity of Alabama at Birmingham, 1802 6th Ave S, Birmingham, AL, 35233, USA.
Fengshen KuoMemorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Essel DulaimiFox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA.
Kathy Q CaiFox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA.
Karthik DevarajanFox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA.
Sejong BaeUniversity of Alabama at Birmingham, 1802 6th Ave S, Birmingham, AL, 35233, USA.
Gurudatta NaikUniversity of Alabama at Birmingham, 1802 6th Ave S, Birmingham, AL, 35233, USA.
Timothy A ChanMemorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Robert UzzoFox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA.
A Ari HakimiMemorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Guru SonpavdeUniversity of Alabama at Birmingham, 1802 6th Ave S, Birmingham, AL, 35233, USA.
Elizabeth PlimackFox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA.
Fox Chase Cancer Center · USMemorial Sloan Kettering Cancer Center · USUniversity of Alabama at Birmingham · USDana-Farber Cancer Institute · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
TOWARDS PRECISION IMMUNO-ONCOLOGY: UNRAVELING THE GENOMIC DETERMINANTS AND MECHANISMS UNDERLYING IMMUNOTHERAPY EFFICACY AND RESISTANCER35CA232097 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHAN, TIMOTHY AN-THY · 2018 to 2024
$7.0M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA013148NCI NIH HHS R35 CA232097
6 · The paper itself

Abstract

backgroundThe tumor immune microenvironment has become the focus of research in clear cell renal cell carcinoma (ccRCC) due to its important role in immune surveillance post nephrectomy. This study investigates the correlation of tumor infiltrating immune cell characteristics with rates of recurrence following surgery in localized ccRCC.

methodsWe morphologically identified and scored tumor infiltrating lymphocytes (TILs) in hematoxylin and eosin (H&E) stained slides of patients with localized ccRCC (stage ≥T1b excluding stage IV). The University of Alabama at Birmingham (UAB) dataset (n = 159) was used to discover and the Fox Chase Cancer Center (FCCC) dataset (n = 198) was used to validate the results of morphologic immune cell analysis. We then performed gene expression analysis using the Immune Profile panel by NanoString in the UAB cohort and identified immune cells and pathways associated with recurrence, followed by validation in the Cancer Genome Atlas (TCGA) ccRCC dataset. Infiltrating immune cell types were identified by gene expression deconvolution.

resultsThe presence of TILs identified by morphology correlated with higher T cell, Th1, CD8+ T and Treg gene signatures. Recurrence was associated with lower T cells and higher neutrophils. Higher Teffector (Teff)/Treg ratio correlated with lower rate of recurrence and was validated in the TCGA dataset. Genes associated with adaptive immune response were downregulated in tumors that recurred. Unsupervised hierarchical clustering identified a subset of patients with over-expression of adaptive response genes including CD8, CD3, GZMA/B, PRF1, IDO1, CTLA4, PDL1, ICOS and TIGIT. These patients had higher morphologic lymphocyte infiltration and T cell gene expression. Higher levels of TILs identified by morphology correlated with higher rates of recurrence in our discovery dataset but not in our validation set.

conclusionsRecurrence of ccRCC following surgery was associated with lower T cell infiltrate, lower adaptive immune response and higher neutrophil gene expression. Presence of higher Teff/Treg ratio correlated with lower recurrence.

Indexed as

Carcinoma, Renal CellFemaleGene ExpressionHumansImmunotherapyKidney NeoplasmsLymphocytes, Tumor-InfiltratingMaleMiddle AgedPrognosisTumor MicroenvironmentImmune cellImmunotherapyLocalizedRenal cell carcinomaTumor infiltrating lymphocytes

Identifiers

PMID31138299
PMCPMC6540413
OpenAlexW2947691713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.